First amendment to co-development and licensing agreement for naproxen and esomeprazole combination for painCo-Development and Licensing Agreement • March 13th, 2021
Contract Type FiledMarch 13th, 2021This Amendment No. 1 to the Collaboration and License Agreement (this “Amendment”) is made effective as of September 6, 2007 (the “Amendment Effective Date”) by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“AstraZeneca”).